Primo-indication
NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
Intervention Type
Pharmaceutical
Solid/Hematological
Solid
Cancer Type
Prostate
Therapy Types
Hormone Therapy
Regulatory
FDA
N/A
Regulatory Pathway: n/a
EMA
27.03.2020
Regulatory Pathway: standard approval
Availability in other countries
N/A
Focus Area
Cancer
ASMR
III
Medical Need
Partially met
SMR
IMPORTANT
Orphan Status
No